Metagenomi Q1 Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy MGX?
Source: seekingalpha
- Earnings Performance: Metagenomi reported a Q1 GAAP EPS of -$0.61, missing expectations by $0.06, indicating challenges in profitability that may impact investor confidence.
- Collaboration Revenue Decline: The collaboration revenue for Q1 was $1.25M, down 69.7% year-over-year and missing the target by $4.67M, reflecting difficulties in business expansion and partnerships that could hinder future growth potential.
- Cash Reserves Status: As of March 31, 2026, Metagenomi had $140.2 million in cash, cash equivalents, and available-for-sale marketable securities, providing some liquidity, but ongoing losses may threaten its financial stability.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance towards Metagenomi's future performance, particularly as the company relies on collaboration revenue for growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MGX
Wall Street analysts forecast MGX stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.350
Low
7.00
Averages
8.67
High
12.00
Current: 1.350
Low
7.00
Averages
8.67
High
12.00
About MGX
Metagenomi Therapeutics, Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. It is developed to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. It focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. MGX-001, its lead, wholly owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. MGX-001 is designed to insert a Factor VIII (FVIII) DNA cassette into a safe harbor location within an intron of the albumin gene.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Metagenomi Q1 Earnings Miss Expectations
- Earnings Performance: Metagenomi reported a Q1 GAAP EPS of -$0.61, missing expectations by $0.06, indicating challenges in profitability that may impact investor confidence.
- Collaboration Revenue Decline: The collaboration revenue for Q1 was $1.25M, down 69.7% year-over-year and missing the target by $4.67M, reflecting difficulties in business expansion and partnerships that could hinder future growth potential.
- Cash Reserves Status: As of March 31, 2026, Metagenomi had $140.2 million in cash, cash equivalents, and available-for-sale marketable securities, providing some liquidity, but ongoing losses may threaten its financial stability.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance towards Metagenomi's future performance, particularly as the company relies on collaboration revenue for growth.
See More
Investigation into Metagenomi Directors' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Metagenomi Therapeutics, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders can pursue legal remedies without upfront costs, thereby lowering the barrier to participation in the investigation.
- Potential Remedies: Long-term shareholders may seek corporate governance reforms, fund recovery, or court-approved financial awards, which can enhance transparency and accountability, ultimately increasing shareholder value.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
See More
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
See More
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
See More
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
See More
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
See More
Metagenomi Q1 Earnings Miss Expectations
- Earnings Performance: Metagenomi reported a Q1 GAAP EPS of -$0.61, missing expectations by $0.06, indicating challenges in profitability that may impact investor confidence.
- Collaboration Revenue Decline: The collaboration revenue for Q1 was $1.25M, down 69.7% year-over-year and missing the target by $4.67M, reflecting difficulties in business expansion and partnerships that could hinder future growth potential.
- Cash Reserves Status: As of March 31, 2026, Metagenomi had $140.2 million in cash, cash equivalents, and available-for-sale marketable securities, providing some liquidity, but ongoing losses may threaten its financial stability.
- Market Reaction Outlook: Given the disappointing earnings report, investors may adopt a cautious stance towards Metagenomi's future performance, particularly as the company relies on collaboration revenue for growth.
See More
Investigation into Metagenomi Directors' Fiduciary Duties
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of Metagenomi Therapeutics, Inc. breached their fiduciary duties to shareholders, which could impact corporate governance and shareholder rights.
- Legal Fee Arrangement: The firm operates on a contingency fee basis, meaning shareholders can pursue legal remedies without upfront costs, thereby lowering the barrier to participation in the investigation.
- Potential Remedies: Long-term shareholders may seek corporate governance reforms, fund recovery, or court-approved financial awards, which can enhance transparency and accountability, ultimately increasing shareholder value.
- Importance of Shareholder Participation: Involvement from shareholders can improve company policies and oversight mechanisms; Halper Sadeh LLC represents investors globally in seeking compensation for securities fraud and corporate misconduct, having successfully implemented reforms that recovered millions for defrauded investors.
See More
OPENAI CFO SARAH FRIAR ANNOUNCES PARTICIPATION OF A16Z, D.E. SHAW VENTURES, MGX, TPG, AND T. ROWE PRICE IN FUNDING ROUND
Funding Round Announcement: OpenAI, along with several venture capital firms including C.F.O. Sarah Friar, is participating in a new funding round.
Investors Involved: The funding round includes notable investors such as 16Z, D.E. Shaw Ventures, MGX, TPG, and T. Rowe Price.
See More
Metagenomi Reports FY Earnings with Significant Revenue Decline
- Earnings Report: Metagenomi's FY GAAP EPS stands at -$2.36, aligning with market expectations, yet the overall performance fails to boost investor confidence amid challenging market conditions.
- Revenue Decline: The company reported revenue of $25.2 million, reflecting a significant 51.8% year-over-year decline, missing the market estimate of $28.43 million, indicating severe operational challenges.
- Market Reaction: The revenue miss is likely to negatively impact Metagenomi's stock price, as investor confidence in the company's future growth potential diminishes in light of disappointing financial results.
- Industry Context: With increasing competition in the health tech sector, Metagenomi must implement effective strategies to restore growth and enhance its market share to navigate these turbulent times.
See More
Metagenomi Therapeutics Renames Company, Plans IND Submission for MGX-001 in 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic focus on late-stage preclinical assets, aiming to leverage its advanced gene-editing capabilities to drive the success of therapeutic programs, particularly in hemophilia A.
- Clinical Advancement: MGX-001 has demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, with plans to submit IND/CTA in Q4 2026 and initiate first-in-human studies in 2027.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring financial stability while advancing MGX-001 and other therapeutic projects, thereby enhancing investor confidence.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other potential therapies, showcasing its strong competitiveness and market potential in the gene therapy sector.
See More
Metagenomi Therapeutics Renames to Reflect Focus on Gene Therapy, MGX-001 IND Submission Planned for 2026
- Strategic Evolution: Metagenomi Therapeutics has changed its name to reflect its strategic evolution focused on late-stage preclinical assets, particularly the MGX-001 program for hemophilia A, which is expected to submit IND/CTA in 2026, marking a significant advancement in gene therapy.
- Clinical Readiness: MGX-001 demonstrated curative FVIII activity in non-human primates with no identifiable off-target editing, supporting its potential as a best-in-class treatment, with plans to initiate first-in-human studies in 2027 to further advance clinical development.
- Cash Runway: The company anticipates a cash runway extending through Q4 2027, ensuring sufficient funding to support the advancement of MGX-001 and other therapeutic projects, thereby enhancing its competitive position in the market.
- Pipeline Prioritization: Through strategic pipeline prioritization, Metagenomi is focusing on MGX-001 and other secreted protein deficiencies, showcasing the company's strong technological capabilities and promising market outlook in the field of gene editing.
See More
